Second Zantac Cancer Trial Ends With Hung Jury: U.S. News & World Report Coverage

In a closely watched trial, a second jury has failed to reach a verdict in a case involving the popular heartburn medication Zantac and its alleged link to cancer. The trial, which took place in a federal court in California, ended with a hung jury after days of deliberation.

The lawsuit, brought by a group of plaintiffs who claim that their use of Zantac led to their cancer diagnoses, has garnered national attention as more and more consumers question the safety of the widely-used medication. The plaintiffs argue that Zantac contains a carcinogenic substance called NDMA, which has been linked to various types of cancer.

The defense, on the other hand, maintains that Zantac is safe for use and that the plaintiffs’ cancer diagnoses are not related to their use of the medication. They argue that the levels of NDMA found in Zantac are within acceptable limits set by regulatory agencies.

This hung jury comes just weeks after another Zantac trial also ended without a verdict. The outcome of these trials has left many wondering about the future of Zantac and whether more lawsuits will follow.

As the debate over the safety of Zantac continues, consumers are advised to speak with their healthcare providers about any concerns they may have regarding their use of the medication. The next steps in this legal battle remain uncertain, but one thing is clear – the controversy surrounding Zantac is far from over.